Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV000019655 | SCV002790190 | likely pathogenic | Hereditary antithrombin deficiency | 2022-02-08 | criteria provided, single submitter | clinical testing | |
Juno Genomics, |
RCV000019655 | SCV005417487 | likely pathogenic | Hereditary antithrombin deficiency | criteria provided, single submitter | clinical testing | PM2_Supporting+PP3+PS4_Moderate+PP4_Moderate | |
Labcorp Genetics |
RCV000019655 | SCV005816757 | pathogenic | Hereditary antithrombin deficiency | 2024-08-30 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 148 of the SERPINC1 protein (p.Ser148Pro). This variant is present in population databases (rs121909569, gnomAD 0.02%). This missense change has been observed in individual(s) with antithrombin III deficiency (PMID: 24613695, 35720094; internal data). This variant is also known as p.Ser116Pro. ClinVar contains an entry for this variant (Variation ID: 18039). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt SERPINC1 protein function with a negative predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. |
OMIM | RCV000019655 | SCV000039953 | pathogenic | Hereditary antithrombin deficiency | 1993-03-01 | no assertion criteria provided | literature only |